<span item_type="fundamental" item_id="00aedce933f65fb2c71d4b56a40b81bb" counter_id="ST/US/SBFMW" env="prod"></span><span item_type="announcement" item_id="548730062582452481" env="prod"></span><p>Revenue: As of FY2025 Q2, the actual value is USD 9.41 M.</p><p>EPS: As of FY2025 Q2, the actual value is USD -0.39.</p><p></p><h3>Segment Revenue</h3><ul><li>Revenue for the three months ended June 30, 2025, was $9,410,230, compared to $9,303,067 for the same period in 2024.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1402328/000168316825005981/sunshine_i10q-063025.htm"></span></li><li>Revenue for the six months ended June 30, 2025, was $18,311,571, compared to $16,844,113 for the same period in 2024.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1402328/000168316825005981/sunshine_i10q-063025.htm"></span></li></ul><h3>Operational Metrics</h3><ul><li>Gross profit for the three months ended June 30, 2025, was $3,422,866, compared to $2,356,257 for the same period in 2024.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1402328/000168316825005981/sunshine_i10q-063025.htm"></span></li><li>Gross profit for the six months ended June 30, 2025, was $6,153,292, compared to $4,710,594 for the same period in 2024.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1402328/000168316825005981/sunshine_i10q-063025.htm"></span></li><li>Net loss for the three months ended June 30, 2025, was - $1,770,834, compared to - $494,300 for the same period in 2024.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1402328/000168316825005981/sunshine_i10q-063025.htm"></span></li><li>Net loss for the six months ended June 30, 2025, was - $2,950,605, compared to - $1,778,101 for the same period in 2024.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1402328/000168316825005981/sunshine_i10q-063025.htm"></span></li></ul><h3>Cash Flow</h3><ul><li>Net cash used in operating activities was - $2,987,267 for the six months ended June 30, 2025, compared to - $7,762,942 for the same period in 2024.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1402328/000168316825005981/sunshine_i10q-063025.htm"></span></li><li>Cash flows used in investing activities were - $667,802 for the six months ended June 30, 2025, compared to - $1,210,944 for the same period in 2024.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1402328/000168316825005981/sunshine_i10q-063025.htm"></span></li><li>Cash flows provided by financing activities were $3,948,372 for the six months ended June 30, 2025, compared to $5,369,566 for the same period in 2024.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1402328/000168316825005981/sunshine_i10q-063025.htm"></span></li></ul><h3>Future Outlook and Strategy</h3><ul><li>The company aims to increase sales and streamline operations to reduce expenses, focusing on lowering the cost of goods sold from approximately 65% to 60% to achieve breakeven and reduce dependency on capital markets.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1402328/000168316825005981/sunshine_i10q-063025.htm"></span></li><li>Sunshine Biopharma plans to launch 17 additional drugs in 2026, addressing various health areas, which is expected to strengthen its presence in the Canadian generic drug market.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1402328/000168316825005981/sunshine_i10q-063025.htm"></span></li></ul>

SUNSHINE BIOPHARMA INC C/WTS (TO PUR COM) | 10-Q: FY2025 Q2 Revenue: USD 9.41 M